Mountain Pacific Investment Advisers’s CONMED CNMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-13,017
Closed -$460K – 147
2026
Q1
$460K Sell
13,017
-1,761
-12% -$71.7K 0.08% 106
2025
Q4
$600K Sell
14,778
-12,986
-47% -$565K 0.1% 98
2025
Q3
$1.31M Sell
27,764
-112,031
-80% -$5.81M 0.2% 74
2025
Q2
$7.28M Buy
139,795
+4,959
+4% +$272K 0.53% 42
2025
Q1
$8.14M Sell
134,836
-2,978
-2% -$192K 0.61% 38
2024
Q4
$9.43M Sell
137,814
-2,507
-2% -$175K 0.66% 39
2024
Q3
$10.1M Sell
140,321
-4,627
-3% -$326K 0.69% 37
2024
Q2
$10M Sell
144,948
-103,356
-42% -$7.54M 0.75% 38
2024
Q1
$19.9M Buy
248,304
+55,878
+29% +$4.98M 1.11% 32
2023
Q4
$21.1M Buy
192,426
+48,050
+33% +$4.97M 1.31% 28
2023
Q3
$14.6M Buy
144,376
+11,538
+9% +$1.33M 1.01% 32
2023
Q2
$18.1M Buy
132,838
+2,525
+2% +$308K 1.2% 33
2023
Q1
$13.5M Buy
130,313
+4,878
+4% +$472K 0.96% 35
2022
Q4
$11.1M Buy
125,435
+54,390
+77% +$4.51M 0.81% 38
2022
Q3
$5.7M Buy
+71,045
New +$6.7M 0.45% 46

Other funds holding CNMD

Mountain Pacific Investment Advisers's CNMD Position: Q2 2026 in Review

Mountain Pacific Investment Advisers sold out of CONMED (CNMD) in Q2 2026, closing a stake of 13,017 shares — an estimated $460K sold.

Mountain Pacific Investment Advisers first reported a position in CNMD in Q3 2022 and held it in 15 quarters. The position peaked at $21.1M in Q4 2023. 246 funds tracked by Wall St. Rank hold CNMD as of Q2 2026.

  • Mountain Pacific Investment Advisers reported no remaining CONMED position as of Q2 2026 after selling out during the quarter.
  • Mountain Pacific Investment Advisers sold 13,017 CONMED shares in Q2 2026, an estimated $460K.
  • Mountain Pacific Investment Advisers first reported a position in CONMED in Q3 2022 and held it in 15 quarters.
  • Mountain Pacific Investment Advisers's CONMED position peaked at $21.1M in Q4 2023.
  • 246 funds tracked by Wall St. Rank held CONMED as of Q2 2026.

Based on Mountain Pacific Investment Advisers's 13F filing for Q2 2026, filed 30 Jul 2026.